Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent radiotherapy plus intrathecal pemetrexed vs intrathecal pemetrexed alone for refractory leptomeningeal metastases from lung adenocarcinoma
ChiCTR2500110037Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemetrexed in leptomeningeal metastases from lung adenocarcinoma (LM) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Intracranial progression-free survival (iPFS). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
pemetrexed
03
Conditions
leptomeningeal metastases from lung adenocarcinoma (LM)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500110037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110037.